<!doctype html>
<html>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Nayan Lab | Madhur Nayan</title> <meta name="author" content="Nayan Lab | Madhur Nayan"/> <meta name="description" content="Nayan Lab, New York University"/> <meta name="keywords" content="urology, ai, machine learning, oncology"/> 
<link href="index.css" rel="stylesheet" type="text/css">

<div class="container">
	
<body>
	<div class="header">
<h1>Nayan LabÂ | Madhur Nayan, MD.CM., Ph.D.</h1>
	</div>
<p>&nbsp;</p>
<p>I am a Urologic Oncologist and an <a href="https://nyulangone.org/doctors/1700413408/madhur-nayan" target="new">Assistant Professor of Urology at New York University.</a></p>
<p>&nbsp;</p>
<p>My clinical practice focuses on the diagnosis and treatment of cancers of the urinary tract including cancers of the kidney, bladder, and prostate. My research interests are in developing a learning health care system using machine learning methods and electronic health records. I am the founder of <a href="https://www.urologyschool.com" target="new">UrologySchool.com.</a></p>
<p>&nbsp;</p>
<p>Previously, I was fellow in the Combined Harvard Program in Urologic Oncology and a co-instructor for 6.7930/HST.956 &quot;Machine Learning for Healthcare&quot; at the Massachussetts Institute of Technology.  I completed the Surgeon-Scientist Program at the University of Toronto, with a Ph.D. in Clinical Epidemiology and Health Care Research, and medical school at McGill University.</p>
<p>&nbsp;</p>
<h2>Recent Publications</h2>
<ol>
  <li><strong>Nayan M,</strong> Carvalho FLF, Feldman AS. <a href="https://pubmed.ncbi.nlm.nih.gov/35044491/" target="new">Active  surveillance for intermediate risk prostate cancer.</a> World J Urol. 2022  Jan;40(1):79-86. doi: 10.1007/s00345-021-03893-1.: 1-8.</li>
  <li>Carvalho FLF, Wang Y, Dall CP, <strong>Nayan M</strong>,  Chou WH, McGregor B, Sopfkuchen-Evans MF, Stamatakis L, Preston MA, Kibel AS,  Chang SL, Mossanen M. <a href="https://pubmed.ncbi.nlm.nih.gov/35690547/" target="new">Preoperative anemia is associated with increased radical  cystectomy complications.</a> Urol Oncol. 2022 Aug;40(8):382.e7-382.e13. doi:  10.1016/j.urolonc.2022.04.014.</li>
  <li>Cheung DC, Martin LJ, Jivraj NK, Clarke H, Gomes  T, Wijeysundera DN, Diong C, <strong>Nayan M</strong>, Saarela O, Alibhai SMH,  Komisarenko M, Fleshner NE, Kulkarni GS, Finelli A. <a href="https://pubmed.ncbi.nlm.nih.gov/35182588/" target="new">Opioid Use After  Nephrectomy for Kidney Cancer in Ontario: A Population-Based Study.</a> Urology.  2022 Jun;164:118-123. doi: 10.1016/j.urology.2022.02.002.</li>
</ol>
<p>&nbsp;</p>
<p>&nbsp;</p>
</body>
</div>	
	
</html>
